NCT07358910

Brief Summary

RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies. RACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia. Mathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10,000

participants targeted

Target at P75+ for all trials

Timeline
16mo left

Started Dec 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress28%
Dec 2025Sep 2027

Study Start

First participant enrolled

December 18, 2025

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

January 14, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 22, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 16, 2026

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2027

Expected
Last Updated

January 22, 2026

Status Verified

January 1, 2025

Enrollment Period

4 months

First QC Date

January 14, 2026

Last Update Submit

January 14, 2026

Conditions

DengueChikungunyaZika Virus InfectionJapanese EncephalitisWest Nile VirusTick-borne Encephalitis (TBE)Severe Fever With Thrombocytopenia SyndromeNipah Virus InfectionHantavirus InfectionsHepatitis EBrucellosisQ FeverLeptospirosisMelioidosisInfluenza A and BMalariaYellow FeverMayaro FeverUsutu Virus InfectionOropouche FeverRift Valley FeverArenavirus InfectionsMeaslesMumpsRubellaHuman Papilloma Virus (HPV)Rotavirus DiseasePertussisDiphteriaTetanusVaricellaHepatitis ANorovirus InfectionsEnterovirusAdenovirusRhinovirusParvovirusRespiratory Syncytial Virus (RSV)CytomegalovirusEpstein Barr VirusSalmonella TyphiVibrio CholeraeLegionella Pneumophila PneumoniaMycoplasmaChlamydiaLymphatic FilariasisToxoplasma GondiiGiardiasisEntamoeba HistolyticaLeishmaniasisStrongyloides Stercoralis InfectionAscaris LumbricoidesTrichuris TrichiuraClonorchis SinensisOpisthorchis ViverriniSchistosomiasisStreptococcus PneumoniaeMeningitis

Keywords

Infectious diseaseOne HealthPopulation-based surveyNationally representative surveySeroepidemiologyMultiplex serologySeroprevalenceVector-borne diseasesZoonosesVaccine-preventable diseasesNeglected tropical diseasesTransmission dynamicsForce of infectionMathematical modellingSpatial epidemiologyPrecision public healthCambodia

Outcome Measures

Primary Outcomes (1)

  • Seroprevalence of antibodies against an established panel of priority pathogens in the surveyed human populations:

    The proportion of sampled individuals with detectable antibodies against this priority panel of pathogens, measured using multiplex serological assays.

    At the time of blood sampling during household visits, over the inclusion period from December 2025 to April 2026.

Study Arms (1)

Human Community Cohort (National Population Sample)

Probability-based, multi-stage population sample of \~10,000 participants (2-75 years old) recruited across urban and rural communities nationwide. Data include standardized questionnaires (demography, health conditions, mobility, animal contact, healthcare access) and serum biospecimens for multiplex serology;

Eligibility Criteria

Age2 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study population comprises approximately 10,000 participants aged 2 to 75 years, drawn from 4,160 households across Cambodia's 25 provinces. Households will be randomly selected from 104 villages to ensure a nationally representative sample that reflects the country's diverse geographic and demographic characteristics. Participants will provide detailed socio-demographic information, enabling post-stratification weighted analysis of the sample's structure by sex, age, and geographic area to facilitate the extrapolation of findings to the entire population, ensuring that the study's conclusions are broadly applicable.

You may qualify if:

  • Residency in the village for more than 6 months;
  • For adults: provision of written consent;
  • For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;

You may not qualify if:

  • Unable to understand or consent;
  • Under guardianship or deprived of liberty;
  • Medical conditions that impede survey participation;
  • Refusal to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institut Pasteur du Cambodge

Phnom Penh, Phnom Penh, 12201, Cambodia

RECRUITING

Related Links

Biospecimen

Retention: SAMPLES WITHOUT DNA

Human serum aliquots derived from venous blood collected in dry tubes and stored at ≤-80 °C for multiplex serology. In selected workflows, pathogen nucleic acids may be generated for testing but are not retained. Co-located animal specimens include sera (poultry, pigs, dogs, cattle, sheep/goats) and oral/rectal swabs; rodent specimens collected near households for laboratory testing. These samples are processed and archived according to standardized procedures. Environmental specimens retained include surface swabs, water samples (with 0.2 µm filtrates/membranes), air and soil samples from high-risk human-animal-environment interfaces. Vector collections (mosquito specimens obtained with BG-traps) are retained for entomological and pathogen investigations. All retained specimens are aliquoted as appropriate and stored in the IPC biobank under controlled temperatures for up to 15 years.

MeSH Terms

Conditions

DengueChikungunya FeverZika Virus InfectionEncephalitis, JapaneseEncephalitis, Tick-BorneSevere Fever with Thrombocytopenia SyndromeHenipavirus InfectionsHantavirus InfectionsHepatitis EBrucellosisQ FeverLeptospirosisMelioidosisMalariaYellow FeverBunyaviridae InfectionsRift Valley FeverArenaviridae InfectionsMeaslesMumpsRubellaRotavirus InfectionsWhooping CoughTetanusChickenpoxHepatitis ACaliciviridae InfectionsEnterovirus InfectionsAdenoviridae InfectionsParvoviridae InfectionsEpstein-Barr Virus InfectionsMycoplasma InfectionsChlamydia InfectionsElephantiasis, FilarialGiardiasisLeishmaniasisTrichuriasisSchistosomiasisMeningitisCommunicable DiseasesVector Borne DiseasesZoonosesVaccine-Preventable DiseasesNeglected Diseases

Condition Hierarchy (Ancestors)

Mosquito-Borne DiseasesInfectionsArbovirus InfectionsVirus DiseasesFlavivirus InfectionsFlaviviridae InfectionsRNA Virus InfectionsHemorrhagic Fevers, ViralAlphavirus InfectionsTogaviridae InfectionsEncephalitis, ArbovirusEncephalitis, ViralCentral Nervous System Viral DiseasesCentral Nervous System InfectionsInfectious EncephalitisEncephalitisBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeuroinflammatory DiseasesTick-Borne DiseasesParamyxoviridae InfectionsMononegavirales InfectionsHepatitis, Viral, HumanHepatitisLiver DiseasesDigestive System DiseasesGram-Negative Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesSpirochaetales InfectionsBurkholderia InfectionsProtozoan InfectionsParasitic DiseasesHepatitis, Viral, AnimalHepatitis, AnimalAnimal DiseasesMorbillivirus InfectionsRubulavirus InfectionsParotitisParotid DiseasesSalivary Gland DiseasesMouth DiseasesStomatognathic DiseasesRubivirus InfectionsReoviridae InfectionsBordetella InfectionsRespiratory Tract InfectionsRespiratory Tract DiseasesClostridium InfectionsGram-Positive Bacterial InfectionsVaricella Zoster Virus InfectionHerpesviridae InfectionsDNA Virus InfectionsPicornaviridae InfectionsTumor Virus InfectionsMycoplasmatales InfectionsChlamydiaceae InfectionsSexually Transmitted Diseases, BacterialSexually Transmitted DiseasesGenital DiseasesUrogenital DiseasesFilariasisSpirurida InfectionsSecernentea InfectionsNematode InfectionsHelminthiasisLymphedemaLymphatic DiseasesHemic and Lymphatic DiseasesIntestinal Diseases, ParasiticIntestinal DiseasesGastrointestinal DiseasesEuglenozoa InfectionsSkin Diseases, ParasiticSkin Diseases, InfectiousSkin DiseasesSkin and Connective Tissue DiseasesEnoplida InfectionsAdenophorea InfectionsTrematode InfectionsDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Claude Flamand, Ph.D.

    Institut Pasteur du Cambodge

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Claude Flamand, Ph.D.

CONTACT

+855012333650cflamand@pasteur-kh.org

Najet Hadhri, MSc.

CONTACT

+34661400698nhadhri@pasteur-kh.org

Study Design

Study Type
observational
Observational Model
FAMILY BASED
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 14, 2026

First Posted

January 22, 2026

Study Start

December 18, 2025

Primary Completion

April 16, 2026

Study Completion (Estimated)

September 30, 2027

Last Updated

January 22, 2026

Record last verified: 2025-01

Locations

CA(1)